Current Edition


Adagio, after bold promises, says antibody drug won’t work well against omicron

The findings are a huge disappointment for Adagio, which billed ADG20 as a weapon that could neutralize a wide range of variants and help with …

Continue Reading →

Roche cuts ties with Atea after COVID-19 pill’s trial failure

Roche’s seeming lack of confidence in the future of AT-527 appears to be weighing on investors. Atea shares, which soared above $88 in February 2021, …

Continue Reading →
clinical trial

FDA approves Merck’s Keytruda as first immunotherapy for early kidney cancer

Approval of Keytruda in this setting comes about six months after Merck revealed early results from a study called Keynote-564, which showed the immunotherapy could …

Continue Reading →

Biogen’s closely watched ALS drug comes up short in late-stage study

An experimental drug for amyotrophic lateral sclerosis missed the main goal of a late-stage clinical trial, marking another setback in attempts to treat the debilitating …

Continue Reading →
cervical cancer

Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

Merck’s Keytruda is the dominant cancer immunotherapy and, of the seven of its type that are approved, the only that’s cleared for use in cervical …

Continue Reading →
clinical trial

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

Merck’s filing comes less than two weeks after the drugmaker showed molnupiravir lowered the risk of hospitalization or death by roughly 50% in a Phase …

Continue Reading →

Hint of benefit in Alzheimer’s drug study fuel stock surge for Swiss biotech

A small clinical trial of a once-failed Alzheimer’s drug offered tantalizing but inconclusive hints of benefit, propelling shares in its biotech maker higher by more …

Continue Reading →